Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Комбинированные быстродействующие бронхолитики в лечении обструктивных заболеваний легких
Комбинированные быстродействующие бронхолитики в лечении обструктивных заболеваний легких
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Авдеев С.Н. Новая бесфреоновая технология ингаляционной терапии. Cons. Med. Пульмонология. (Прил.). 2005; 7 (1).
2. Горячкина Л.А., Дробик О.С. Фармакотерапия обструктивных заболеваний легких: комбинированный бронхолитик Беродуал Н. Справочник поликлинического врача. 2006; 8.
3. Государственный реестр лекарственных средств по состоянию на 02.08.2008.
4. Маркова И.В., Михайлов И.Б, Неженцев М.В. Фармакология. СПб.: Фолиант, 2001.
5. Машковский М.Д. Лекарственные средства. 15-е изд., испр. и доп. М.: Новая волна, 2007.
6. Огородова Л.М., Петровский Ф.И., Петровская Ю.А. Клиническая фармакология бронхиальной астмы. Атмосфера. 2002; 3: 157–60.
7. Цой А.Н., Архипов В.В. Вопросы клинической фармакологии b2-адреностимуляторов. РМЖ. 2001. 9 (21): 930–3.
8. Чучалин А.Г., Авдеев С.Н., Архипов В.В. и др. Рациональная фармакотерапия. Под общей ред. А.Г.Чучалина. М.: Литтерра, 2004; 5.
9. b2-Agonists. From pharmacological properties to everyday
clinical practice: International workshop report. London, 2000.
10. Barnes PJ. New concept in the pathogenesis of bronchial
responsiveness and asthma. J Allergy Clin Immunol 1989; 83: 1013–26.
11. Bradley BL, Azzawi M, Jacobson M et al. Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness. J Allergy Clin Immunol 1991; 88.
12. Dolovich MB, Ahrens RC, Hess DR et al. Device selection and outcomes of aerosol therapy: Evidence based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005; 127: 335–71.
13. Ganderton D, Lewis D, Davies R et al. Modulite: a means of designing the aerosols generated by pressurized metered dose inhalers. Respir Med 2002; 96 (Suppl. D): S3–S8.
14. Ganderton D, Lewis D, Davies R et al. Modulite: a means of designing the aerosols generated by pressurized metered dose inhalers. Respir Med 2002; 96 (Suppl. D): S3–S8.
15. Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 2009; 64 (8): 728–35.
16. Gross N, Tashkin D, Miller R et al. Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group. Respiration 1998; 65: 354–62.
17. Molimard M et al. Long- and short-adrenoreceptor agonists: interactions in human contracted bronchi. Eur Respir J 1998.
18. O’Connor BJ, Alkinan SL, Barnes PJ. Tolerance to the non-bronchodilatator effects of inhaled b2-agonists in asthma. N Engl J Med 1992.
19. O’Driscoll BR, Taylor RJ, Horsley MG et al. Nebulized salbutamol with and wihout ipratropium bromide in acute airflow obstruction. Lancet 1989; 1: 1418–20.
20. Rebuck AS, Chapman KR, Abboud R et al. Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obctructive airways disease in the emergency room. Am J Med 1987; 82: 59–64.
21. Rodrigo G, Rodrigo C, Burschtin O. A meta-analysis of the effects of ipratropium bromide inaduits with acute asthma. Am J Med 1999; 107: 363–70.
22. Rodrigo GJ, Rodrigo C. First-line therapy for adult patients with acute asthma receiving a multiple-dose protocol of ipratropium bromide plus albuterol in the emergency department. Am J Respir Crit Care Med 2000; 161 (6): 1862–8.
23. Taylor DR, Buick B, Kinney C et al. The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible air-flow obstruction. Am Rev Respir Dis 1985; 131: 747–51.
24. Weber EJ, Levitt A, Covington JK, Gambrioli E. Effect of continuously nebulized ipratropium bromide plus albuterol on emergency department length of stay and hospital admission rates in patients with acute bronchospasm. A randomized, controlled trial. Chest 1999; 115: 937–44.
2. Горячкина Л.А., Дробик О.С. Фармакотерапия обструктивных заболеваний легких: комбинированный бронхолитик Беродуал Н. Справочник поликлинического врача. 2006; 8.
3. Государственный реестр лекарственных средств по состоянию на 02.08.2008.
4. Маркова И.В., Михайлов И.Б, Неженцев М.В. Фармакология. СПб.: Фолиант, 2001.
5. Машковский М.Д. Лекарственные средства. 15-е изд., испр. и доп. М.: Новая волна, 2007.
6. Огородова Л.М., Петровский Ф.И., Петровская Ю.А. Клиническая фармакология бронхиальной астмы. Атмосфера. 2002; 3: 157–60.
7. Цой А.Н., Архипов В.В. Вопросы клинической фармакологии b2-адреностимуляторов. РМЖ. 2001. 9 (21): 930–3.
8. Чучалин А.Г., Авдеев С.Н., Архипов В.В. и др. Рациональная фармакотерапия. Под общей ред. А.Г.Чучалина. М.: Литтерра, 2004; 5.
9. b2-Agonists. From pharmacological properties to everyday
clinical practice: International workshop report. London, 2000.
10. Barnes PJ. New concept in the pathogenesis of bronchial
responsiveness and asthma. J Allergy Clin Immunol 1989; 83: 1013–26.
11. Bradley BL, Azzawi M, Jacobson M et al. Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness. J Allergy Clin Immunol 1991; 88.
12. Dolovich MB, Ahrens RC, Hess DR et al. Device selection and outcomes of aerosol therapy: Evidence based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005; 127: 335–71.
13. Ganderton D, Lewis D, Davies R et al. Modulite: a means of designing the aerosols generated by pressurized metered dose inhalers. Respir Med 2002; 96 (Suppl. D): S3–S8.
14. Ganderton D, Lewis D, Davies R et al. Modulite: a means of designing the aerosols generated by pressurized metered dose inhalers. Respir Med 2002; 96 (Suppl. D): S3–S8.
15. Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 2009; 64 (8): 728–35.
16. Gross N, Tashkin D, Miller R et al. Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group. Respiration 1998; 65: 354–62.
17. Molimard M et al. Long- and short-adrenoreceptor agonists: interactions in human contracted bronchi. Eur Respir J 1998.
18. O’Connor BJ, Alkinan SL, Barnes PJ. Tolerance to the non-bronchodilatator effects of inhaled b2-agonists in asthma. N Engl J Med 1992.
19. O’Driscoll BR, Taylor RJ, Horsley MG et al. Nebulized salbutamol with and wihout ipratropium bromide in acute airflow obstruction. Lancet 1989; 1: 1418–20.
20. Rebuck AS, Chapman KR, Abboud R et al. Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obctructive airways disease in the emergency room. Am J Med 1987; 82: 59–64.
21. Rodrigo G, Rodrigo C, Burschtin O. A meta-analysis of the effects of ipratropium bromide inaduits with acute asthma. Am J Med 1999; 107: 363–70.
22. Rodrigo GJ, Rodrigo C. First-line therapy for adult patients with acute asthma receiving a multiple-dose protocol of ipratropium bromide plus albuterol in the emergency department. Am J Respir Crit Care Med 2000; 161 (6): 1862–8.
23. Taylor DR, Buick B, Kinney C et al. The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible air-flow obstruction. Am Rev Respir Dis 1985; 131: 747–51.
24. Weber EJ, Levitt A, Covington JK, Gambrioli E. Effect of continuously nebulized ipratropium bromide plus albuterol on emergency department length of stay and hospital admission rates in patients with acute bronchospasm. A randomized, controlled trial. Chest 1999; 115: 937–44.
Авторы
Н.П.Княжеская, Ю.К.Новиков
Кафедра пульмонологии ФУВ ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздравсоцразвития РФ, Москва
Кафедра пульмонологии ФУВ ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздравсоцразвития РФ, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.